Denk Pharma GmbH & Co. KG

denkpharma.de

DENK PHARMA is a global company with core competence in the area of health care. DENK PHARMA was founded in Munich, Germany in 1948. We have a strong focus on export markets and presently supply our DENK PHARMA premium medicine and food supplements around the world. For more than 70 years, we have delivered quality that is “Made in Germany” – we manufacture, quality control and register all of our products in Germany. This enables us to ensure that all patients worldwide receive the same high-quality as they do in Germany.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

ARROWHEAD PHARMACEUTICALS INITIATES PHASE 1/2 STUDY OF ARO-C3 FOR TREATMENT OF COMPLEMENT MEDIATED DISEASES

Arrowhead Pharmaceuticals Inc. | February 19, 2022

news image

Arrowhead Pharmaceuticals Inc. announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. “We believe a C3 targeted drug has the potential to address multiple complement mediated and complement associated diseases, whe...

Read More

Research

DISPERSOL TECHNOLOGIES ANNOUNCES COLLABORATION WITH AJAX THERAPEUTICS TO DEVELOP ENHANCED KINETISOL DRUG FORMULATIONS

DisperSol Technologies | December 18, 2021

news image

DisperSol Technologies LLC announced that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies. “Ajax is taking an innovative approach to developing a pipeline of selectively targeted small molecules and we look forward to applying our proprietary KinetiSol technology to help enha...

Read More

Business Insights

VETSOURCE UNVEILS NEW BRAND REFLECTING COMPANY'S GROWTH

Vetsource | November 17, 2022

news image

Vetsource®, a pet health company designed to provide innovative pharmacy, technology and business services to those who care for pets, launched a new brand identity to signal the official start of three brands coming together as a single, unified portfolio of solutions for the veterinary industry. Already established as a leading provider of innovative prescription management and home delivery services for veterinary practices and pet owners since 2008, Vetsource announced the...

Read More

Business Insights

FDA GRANTS DIRECT BIOLOGICS REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR THE USE OF EXOFLO IN COVID-19 RELATED ARDS

Direct Biologics | April 13, 2022

news image

Direct Biologics, an innovative biotechnology company with a groundbreaking extracellular vesicle platform drug technology, announced that the U.S. Food and Drug Administration has awarded their EV drug product ExoFlo with a Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of Acute Respiratory Distress Syndrome associated with COVID-19. The RMAT program is designed to expedite the approval of promising regenerative medical products in the US that demonstrate clin...

Read More
news image

Pharmacy Market

ARROWHEAD PHARMACEUTICALS INITIATES PHASE 1/2 STUDY OF ARO-C3 FOR TREATMENT OF COMPLEMENT MEDIATED DISEASES

Arrowhead Pharmaceuticals Inc. | February 19, 2022

Arrowhead Pharmaceuticals Inc. announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. “We believe a C3 targeted drug has the potential to address multiple complement mediated and complement associated diseases, whe...

Read More
news image

Research

DISPERSOL TECHNOLOGIES ANNOUNCES COLLABORATION WITH AJAX THERAPEUTICS TO DEVELOP ENHANCED KINETISOL DRUG FORMULATIONS

DisperSol Technologies | December 18, 2021

DisperSol Technologies LLC announced that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies. “Ajax is taking an innovative approach to developing a pipeline of selectively targeted small molecules and we look forward to applying our proprietary KinetiSol technology to help enha...

Read More
news image

Business Insights

VETSOURCE UNVEILS NEW BRAND REFLECTING COMPANY'S GROWTH

Vetsource | November 17, 2022

Vetsource®, a pet health company designed to provide innovative pharmacy, technology and business services to those who care for pets, launched a new brand identity to signal the official start of three brands coming together as a single, unified portfolio of solutions for the veterinary industry. Already established as a leading provider of innovative prescription management and home delivery services for veterinary practices and pet owners since 2008, Vetsource announced the...

Read More
news image

Business Insights

FDA GRANTS DIRECT BIOLOGICS REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR THE USE OF EXOFLO IN COVID-19 RELATED ARDS

Direct Biologics | April 13, 2022

Direct Biologics, an innovative biotechnology company with a groundbreaking extracellular vesicle platform drug technology, announced that the U.S. Food and Drug Administration has awarded their EV drug product ExoFlo with a Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of Acute Respiratory Distress Syndrome associated with COVID-19. The RMAT program is designed to expedite the approval of promising regenerative medical products in the US that demonstrate clin...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us